ASCENTAGE PHARMA GROUP INTERNATIONAL(AAPG)Earnings, Financials & Key Ratios
AAPG•NASDAQ
Price updated Jun 19, 2026
AboutAscentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.Show more
- Revenue$981M+341.8%
- EBITDA-$277M+64.5%
- Net Income-$405M+56.2%
- EPS (Diluted)-1.34+89.8%
- Gross Margin97.03%+12.5%
- EBITDA Margin-28.2%+92.0%
- Operating Margin-37.7%+90.4%
- Net Margin-41.34%+90.1%
- ROE-235.17%+39.1%
AAPG Key Insights
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 132.2%
✗Weaknesses
- ✗High debt to equity ratio of 6.1x
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AAPG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AAPG Price & Volume
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) stock price & volume — 10-year historical chart
Loading chart...
AAPG Growth Metrics
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years132.25%
3 Years227.53%
TTM264.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM84.45%
Return on Capital
10 Years-35.3%
5 Years-41.77%
3 Years-37.23%
Last Year-24.51%
AAPG Recent Earnings
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (50%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
Mar 24, 2026Metric
Actual
Est
EPS
$0.65+21.7%
$0.83
Rev
$49M+11.5%
$44M
Q3 2025
Aug 20, 2025Metric
Actual
Est
EPS
$0.96
—
Rev
$33M
—
Q2 2025
Mar 27, 2025Metric
Actual
Est
EPS
$1.00-6134.6%
$0.02
Rev
$21M
—
Q4 2024
Dec 31, 2024Metric
Actual
Est
EPS
$0.25
—
Rev
$21M
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.65vs $0.83+21.7% | $49Mvs $44M+11.5% |
| Q3 2025 | Aug 20, 2025 | $0.96 | $33M |
| Q2 2025 | Mar 27, 2025 | $1.00vs $0.02-6134.6% | $21M |
| Q4 2024 | Dec 31, 2024 | $0.25 | $21M |
Based on last 12 quarters of dataView full earnings history →
AAPG Peer Comparison
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BCAB | 4.61M | 3.66 | -0.07 | -81.82% | -25.31% | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 JAZZ | 14.09B | 224.66 | -38.47 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare AAPG vs Peers
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AAPG Income Statement
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.67M | 6.33M | 6.81M | 14.51M | 12.45M | 27.91M | 209.71M | 221.98M | 980.65M | 1.29B |
Revenue Growth % | - | -17.46% | 7.57% | 113.21% | -14.21% | 124.18% | 651.38% | 5.85% | 341.77% | 264.84% |
Cost of Goods Sold | 261K | 0 | 0 | 2.1M | 1.97M | 3.33M | 22M | 30.54M | 29.09M | 63.13M |
COGS % of Revenue | 3.4% | - | - | 14.44% | 15.79% | 11.92% | 10.49% | 13.76% | 2.97% | - |
Gross Profit | 7.41M▲ 0% | 6.33M▼ 14.6% | 6.81M▲ 7.6% | 12.42M▲ 82.4% | 10.48M▼ 15.6% | 24.58M▲ 134.5% | 187.71M▲ 663.6% | 191.44M▲ 2.0% | 951.57M▲ 397.1% | 1.23B▲ 0% |
Gross Margin % | 96.6% | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | 95.12% |
Gross Profit Growth % | - | -14.56% | 7.57% | 82.42% | -15.57% | 134.47% | 663.62% | 1.99% | 397.05% | - |
Operating Expenses | 122.03M | 137M | 330.65M | 595.1M | 674.42M | 894.42M | 1.04B | 1.06B | 1.32B | 2.7B |
OpEx % of Revenue | 1591.6% | 2164.92% | 4857.51% | 4100.48% | 5417.07% | 3204.65% | 494.74% | 479.35% | 134.74% | - |
Selling, General & Admin | 17.71M | 13.4M | 89.72M | 98.85M | 64.06M | 191.26M | 328.02M | 376.46M | 383.12M | 822.4M |
SG&A % of Revenue | 230.95% | 211.84% | 1318.01% | 681.13% | 514.52% | 685.28% | 156.41% | 169.59% | 39.07% | - |
Research & Development | 102.69M | 118.81M | 249.56M | 463.88M | 564.57M | 766.49M | 743.1M | 706.97M | 947.25M | 1.87B |
R&D % of Revenue | 1339.4% | 1877.61% | 3666.3% | 3196.33% | 4534.71% | 2746.3% | 354.35% | 318.48% | 96.59% | - |
Other Operating Expenses | 1.63M | 4.78M | -8.63M | 32.37M | 45.8M | -63.34M | -33.6M | -19.36M | -9.07M | -2K |
Operating Income | -114.62M▲ 0% | -130.67M▼ 14.0% | -50.25M▲ 61.5% | -582.68M▼ 1059.7% | -663.94M▼ 13.9% | -869.84M▼ 31.0% | -849.81M▲ 2.3% | -872.64M▼ 2.7% | -369.73M▲ 57.6% | -1.46B▲ 0% |
Operating Margin % | -1495% | -2064.92% | -738.14% | -4014.92% | -5332.86% | -3116.57% | -405.23% | -393.11% | -37.7% | -113.24% |
Operating Income Growth % | - | -14% | 61.55% | -1059.68% | -13.95% | -31.01% | 2.3% | -2.69% | 57.63% | - |
EBITDA | -114.46M | -118.17M | -31.78M | -578.86M | -646.98M | -852.65M | -802.39M | -779.44M | -276.56M | -1.31B |
EBITDA Margin % | -1492.86% | -1867.37% | -466.92% | -3988.56% | -5196.59% | -3055.01% | -382.62% | -351.12% | -28.2% | -100.92% |
EBITDA Growth % | - | -3.24% | 73.1% | -1721.26% | -11.77% | -31.79% | 5.89% | 2.86% | 64.52% | 16.32% |
D&A (Non-Cash Add-back) | 164.37K | 12.5M | 18.46M | 3.83M | 16.96M | 17.18M | 47.42M | 93.19M | 93.17M | 159.3M |
EBIT | -104.58M | -62.18M | -46.85M | -1.48B | -669.19M | -815.52M | -834.39M | -836.8M | -330.8M | -1.46B |
Net Interest Income | -3.25M | -57.63M | -29.86M | 8.63M | -1.04M | -9.63M | -43.06M | -63.65M | -26.61M | -43.28M |
Interest Income | 13K | 304K | 7.06M | 12.91M | 5.22M | 7.11M | 9.73M | 32.41M | 37.84M | 5.04M |
Interest Expense | 3.26M | 57.94M | 36.92M | 4.27M | 6.25M | 16.73M | 52.78M | 96.06M | 64.45M | 48.32M |
Other Income/Expense | 6.78M | 10.55M | -23.07M | -899.63M | -11.51M | 37.59M | -37.36M | -60.23M | -25.52M | -48.97M |
Pretax Income | -107.84M▲ 0% | -120.12M▼ 11.4% | -346.91M▼ 188.8% | -1.48B▼ 327.3% | -675.45M▲ 54.4% | -832.25M▼ 23.2% | -887.17M▼ 6.6% | -932.86M▼ 5.2% | -395.25M▲ 57.6% | -1.51B▲ 0% |
Pretax Margin % | -1406.53% | -1898.17% | -5096.36% | -10213.71% | -5425.29% | -2981.9% | -423.05% | -420.24% | -40.31% | -117.02% |
Income Tax | 0 | -1.6M | -1.6M | -1.6M | 2.16M | -49.83M | -4.25M | -7.15M | 10.43M | 6.04M |
Effective Tax Rate % | 0% | 1.33% | 0.46% | 0.11% | -0.32% | 5.99% | 0.48% | 0.77% | -2.64% | -0.4% |
Net Income | -107.84M▲ 0% | -118.51M▼ 9.9% | -345.31M▼ 191.4% | -1.48B▼ 328.8% | -677.61M▲ 54.2% | -782.42M▼ 15.5% | -882.92M▼ 12.8% | -925.64M▼ 4.8% | -405.43M▲ 56.2% | -1.52B▲ 0% |
Net Margin % | -1406.53% | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% | -117.46% |
Net Income Growth % | - | -9.9% | -191.36% | -328.81% | 54.24% | -15.47% | -12.84% | -4.84% | 56.2% | 9.36% |
Net Income (Continuing) | -107.84M | -118.51M | -345.31M | -1.48B | -677.61M | -782.42M | -882.92M | -925.71M | -405.68M | -1.52B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M | 9.91M |
EPS (Diluted) | -2.08▲ 0% | -2.29▼ 10.1% | -6.67▼ 191.3% | -28.01▼ 319.9% | -12.56▲ 55.2% | -12.28▲ 2.2% | -13.40▼ 9.1% | -13.12▲ 2.1% | -1.34▲ 89.8% | -4.45▲ 0% |
EPS Growth % | - | -10.1% | -191.27% | -319.94% | 55.16% | 2.23% | -9.12% | 2.09% | 89.79% | 84.45% |
EPS (Basic) | -2.08 | -2.29 | -6.67 | -28.01 | -12.56 | -12.28 | -13.40 | -13.12 | -1.34 | - |
Diluted Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M | 341.59M |
Basic Shares Outstanding | 51.77M | 51.77M | 51.77M | 52.87M | 53.98M | 63.65M | 65.92M | 70.57M | 302.06M | 341.48M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
AAPG Balance Sheet
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 463.7M | 414.71M | 990.22M | 909.11M | 1.08B | 1.89B | 1.64B | 1.34B | 1.47B | 1.91B |
Cash & Short-Term Investments | 451.92M | 398.99M | 971.49M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 1.66B |
Cash Only | 294.53M | 14.82M | 957.09M | 878.51M | 1.02B | 1.71B | 1.48B | 1.07B | 1.24B | 1.66B |
Short-Term Investments | 157.39M | 384.17M | 14.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 8.31M | 7.85M | 5.25M | 2.53M | 480K | 54.13M | 61.49M | 163.54M | 99.07M | 78.36M |
Days Sales Outstanding | 395.52 | 452.96 | 281.67 | 63.53 | 14.07 | 707.86 | 107.02 | 268.9 | 36.88 | 84.21 |
Inventory | 0 | 0 | 0 | 0 | 0 | 3.93M | 9.45M | 16.17M | 6.6M | 8.59M |
Days Inventory Outstanding | - | - | - | - | - | 431.02 | 156.77 | 193.2 | 82.79 | 60.82 |
Other Current Assets | 11.22K | 25.18K | 6.42M | 3.95M | 17.31M | 59.26M | 16.6M | 24.54M | 24.63M | 160.31M |
Total Non-Current Assets | 129.64M | 166.95M | 239.16M | 295.94M | 652M | 1.05B | 1.19B | 1.16B | 1.14B | 1.14B |
Property, Plant & Equipment | 4.51M | 25.33M | 33.99M | 110.22M | 477M | 854.3M | 650.02M | 957.23M | 905.86M | 871.96M |
Fixed Asset Turnover | 1.70x | 0.25x | 0.20x | 0.13x | 0.03x | 0.03x | 0.32x | 0.23x | 1.08x | 1.41x |
Goodwill | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M | 24.69M |
Intangible Assets | 87.13M | 80.71M | 108.53M | 104.31M | 97.39M | 60.41M | 84.3M | 85.45M | 76M | 70.99M |
Long-Term Investments | 1.91M | 0 | 0 | 4.62M | 31.77M | 27.84M | 18.53M | 18.95M | 33.86M | 123.35M |
Other Non-Current Assets | 13.31M | 36.22M | 71.94M | 52.1M | 21.13M | 35.88M | 361.93M | 10.05M | 59M | 132.44M |
Total Assets | 593.34M▲ 0% | 581.66M▼ 2.0% | 1.23B▲ 111.4% | 1.21B▼ 2.0% | 1.73B▲ 43.6% | 2.94B▲ 69.8% | 2.83B▼ 3.7% | 2.5B▼ 11.7% | 2.62B▲ 4.7% | 3.05B▲ 0% |
Asset Turnover | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.01x | 0.07x | 0.09x | 0.37x | 0.46x |
Asset Growth % | - | -1.97% | 111.36% | -1.98% | 43.65% | 69.84% | -3.73% | -11.65% | 4.7% | -2.44% |
Total Current Liabilities | 77.62M | 79.53M | 105.27M | 202.06M | 276.15M | 361.11M | 881.15M | 934.17M | 1.17B | 1.24B |
Accounts Payable | 156K | 3.82M | 5.08M | 13.08M | 23.36M | 70.86M | 95.56M | 72.44M | 91.97M | 118.68M |
Days Payables Outstanding | 218.16 | - | - | 2.28K | 4.34K | 7.77K | 1.59K | 865.74 | 1.15K | 529.31 |
Short-Term Debt | 0 | 0 | 35M | 85M | 44.75M | 39.8M | 510.31M | 606.65M | 769.62M | 822.61M |
Deferred Revenue (Current) | 121.02K | 6.6K | 0 | 6.6K | 6.58K | 0 | 24.35M | 38.41M | 54.09M | 92.5M |
Other Current Liabilities | 12.46M | 12.23M | 24.76M | 46.9M | 16.87M | 58.73M | 2.82M | 0 | 0 | 286.84M |
Current Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.22x | 1.86x | 1.44x | 1.26x | 1.54x |
Quick Ratio | 5.97x | 5.21x | 9.41x | 4.50x | 3.91x | 5.21x | 1.85x | 1.42x | 1.26x | 1.53x |
Cash Conversion Cycle | - | - | - | - | - | -6.63K | -1.32K | -403.64 | -1.03K | -384.28 |
Total Non-Current Liabilities | 530.33M | 633.93M | 2.14B | 112.51M | 608.27M | 1.34B | 1.54B | 1.5B | 1.18B | 1.13B |
Long-Term Debt | 0 | 0 | 0 | 0 | 473.06M | 1.03B | 1.27B | 1.17B | 868.64M | 867.11M |
Capital Lease Obligations | 472K | 2.88M | 4.46M | 9.21M | 6.08M | 8.25M | 9.14M | 12.92M | 20.79M | 60.4M |
Deferred Tax Liabilities | 21.76M | 20.16M | 18.56M | 16.96M | 15.36M | 13.75M | 12.15M | 10.55M | 5.37M | 21.77M |
Other Non-Current Liabilities | 499.36M | 594.93M | 2.09B | 51.25M | 73.57M | 52.34M | 35.33M | 18.3M | 6.27M | 248.55M |
Total Liabilities | 607.95M | 713.46M | 2.24B | 314.57M | 884.42M | 1.71B | 2.42B | 2.43B | 2.34B | 2.37B |
Total Debt | 830K | 4.9M | 42.04M | 101.41M | 529.7M | 1.08B | 1.79B | 1.8B | 1.67B | 1.72B |
Net Debt | -293.7M | -9.92M | -915.04M | -777.11M | -490.28M | -622.6M | 317.09M | 726.3M | 431.92M | 54.71M |
Debt / Equity | - | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x | 2.54x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -1.31x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.04x |
Interest Coverage | -35.17x | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x | -30.31x |
Total Equity | -14.61M▲ 0% | -131.8M▼ 802.3% | -1.01B▼ 667.5% | 890.48M▲ 188.0% | 846.62M▼ 4.9% | 1.23B▲ 45.8% | 408.66M▼ 66.9% | 70.63M▼ 82.7% | 274.16M▲ 288.2% | 675.91M▲ 0% |
Equity Growth % | - | -802.35% | -667.53% | 188.03% | -4.92% | 45.84% | -66.9% | -82.72% | 288.16% | 221.86% |
Book Value per Share | -0.28 | -2.55 | -19.54 | 16.84 | 15.68 | 19.40 | 6.20 | 1.00 | 0.91 | 1.98 |
Total Shareholders' Equity | -14.61M | -131.8M | -1.01B | 890.48M | 846.62M | 1.23B | 408.66M | 60.42M | 264.19M | 666M |
Common Stock | 0 | 0 | 63K | 142K | 154K | 178K | 180K | 197K | 214K | 239K |
Retained Earnings | 0 | 0 | -615.82M | -2.1B | -2.77B | -3.56B | -4.44B | -5.37B | -5.77B | -6.36B |
Treasury Stock | 0 | 0 | -4K | -574 | -4K | -470 | -26.55M | -21.35M | -8K | -2.96M |
Accumulated OCI | 0 | 0 | 0 | 0 | -509.81M | -550.95M | -518.51M | -504.46M | -510.59M | -516.07M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.21M | 9.97M | 9.91M |
AAPG Cash Flow Statement
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -45.89M | -107.98M | -237.67M | -460.31M | -609.96M | -604.68M | -653.91M | -726.08M | -111.36M | -468.97M |
Operating CF Margin % | -598.58% | -1706.46% | -3491.51% | -3171.67% | -4899.24% | -2166.53% | -311.82% | -327.09% | -11.36% | - |
Operating CF Growth % | - | -135.3% | -120.09% | -93.68% | -32.51% | 0.87% | -8.14% | -11.04% | 84.66% | 262.4% |
Net Income | -107.84M | -120.12M | -346.91M | -741.16M | -675.45M | -832.25M | -887.17M | -932.86M | -395.25M | -1.52B |
Depreciation & Amortization | 164.37K | 12.5M | 18.46M | 3.83M | 27.42M | 28.33M | 62.91M | 93.19M | 93.17M | 140.79M |
Stock-Based Compensation | 64.99M | 0 | 27.57M | 70.82M | 74.03M | 46.97M | 22.11M | 31.5M | 20.92M | 60.27M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -6.74M | -10.9M | 36.13M | 195.06M | 19.29M | 227.18M | 43.82M | 91.23M | 58.84M | 1.42B |
Working Capital Changes | 2.15M | 10.53M | 27.08M | 11.14M | -55.25M | -74.91M | 104.41M | -9.15M | 110.97M | 18.35M |
Change in Receivables | -301K | 556K | 0 | 0 | 0 | -53.97M | -388K | -91.54M | 62.75M | -28.79M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -3.93M | -5.52M | -6.72M | 9.57M | 2.85M |
Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 24.7M | -23.11M | 19.52M | 0 |
Cash from Investing | -152.61M | -230.35M | 292.81M | -201.33M | -107.37M | -466.52M | -384.61M | 21.92M | -362.04M | -275.34M |
Capital Expenditures | -3.29M | -20.54M | -48.16M | -77.46M | -249.92M | -435.42M | -203.29M | -46.11M | -24.29M | -36.42M |
CapEx % of Revenue | 42.85% | 324.53% | 707.58% | 533.7% | 2007.4% | 1560.07% | 96.94% | 20.77% | 2.48% | 2.82% |
Acquisitions | 6.1M | 0 | -33.38M | 0 | 0 | -36.2M | -20M | -20M | -25.52M | -29.52M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -155.42M | -209.81M | -1.29M | -143.48M | -1.55M | -879K | -31.32M | 88.03M | -312.23M | -209.4M |
Cash from Financing | 435.54M | 58.36M | 860.16M | 442.36M | 1.04B | 1.78B | 619.27M | 368.75M | 314.77M | 227.89M |
Debt Issued (Net) | 0 | 0 | 35M | 50M | 432.81M | 548.59M | 695.87M | -13.36M | -145.34M | -98.85M |
Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | -2M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -25.87M | -26.78M | -5.92M | 0 | -7.88M |
Other Financing | -581K | -2.53M | -85.45M | -39.92M | -27.02M | -41.97M | -49.83M | -82.05M | -73.83M | 334.62M |
Net Change in Cash | 294.53M▲ 0% | -279.71M▼ 195.0% | 942.27M▲ 436.9% | -218.1M▼ 123.1% | 280.99M▲ 228.8% | 686.91M▲ 144.5% | -361.25M▼ 152.6% | -307.59M▲ 14.9% | -144.95M▲ 52.9% | 952.43M▲ 0% |
Free Cash Flow | -49.26M▲ 0% | -128.52M▼ 160.9% | -287.13M▼ 123.4% | -541.72M▼ 88.7% | -861.43M▼ 59.0% | -1.04B▼ 20.9% | -890.88M▲ 14.4% | -782.92M▲ 12.1% | -135.65M▲ 82.7% | -505.39M▲ 0% |
FCF Margin % | -642.55% | -2030.99% | -4218.11% | -3732.66% | -6919.13% | -3730.95% | -424.81% | -352.69% | -13.83% | -39.07% |
FCF Growth % | - | -160.88% | -123.41% | -88.67% | -59.02% | -20.88% | 14.45% | 12.12% | 82.67% | 72.3% |
FCF per Share | -0.95 | -2.48 | -5.55 | -10.25 | -15.96 | -16.36 | -13.52 | -11.09 | -0.45 | -1.48 |
FCF Conversion (FCF/Net Income) | 0.43x | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x | 0.33x |
Interest Paid | 49K | 257K | 1.89M | 4.27M | 5.93M | 16.81M | 49.85M | 92.35M | 60.56M | 98.53M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AAPG Key Ratios
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | - | -166.28% | -78.02% | -75.18% | -107.45% | -386.25% | -235.17% | -224.81% |
Return on Invested Capital (ROIC) | - | - | -385.48% | -212.03% | -134.72% | -95.28% | -85.96% | -36.9% | -121.74% |
Gross Margin | 100% | 100% | 85.56% | 84.21% | 88.08% | 89.51% | 86.24% | 97.03% | 95.12% |
Net Margin | -1872.85% | -5072.82% | -10202.67% | -5442.62% | -2803.38% | -421.02% | -416.98% | -41.34% | -117.46% |
Debt / Equity | - | - | 0.11x | 0.63x | 0.88x | 4.39x | 25.42x | 6.09x | 2.54x |
Interest Coverage | -2.26x | -1.36x | -136.33x | -106.15x | -51.99x | -16.10x | -9.08x | -5.74x | -30.31x |
FCF Conversion | 0.91x | 0.69x | 0.31x | 0.90x | 0.77x | 0.74x | 0.78x | 0.27x | 0.33x |
Revenue Growth | -17.46% | 7.57% | 113.21% | -14.21% | 124.18% | 651.38% | 5.85% | 341.77% | 264.84% |
Related:AAPG Dividend History·AAPG Revenue History·AAPG Price History·AAPG P/E History·AAPG Financial Ratios·AAPG Institutional Holders
AAPG Frequently Asked Questions
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported $1.29B in revenue for fiscal year 2024. This represents a 16773% increase from $7.7M in 2016.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) grew revenue by 341.8% over the past year. This is strong growth.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) reported a net loss of $1.52B for fiscal year 2024.
Dividend & Returns
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) has a return on equity (ROE) of -235.2%. Negative ROE indicates the company is unprofitable.
ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) had negative free cash flow of $505.4M in fiscal year 2024, likely due to heavy capital investments.